Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Capricor Therapeutics Inc

CAPR ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: HOLD

Last Close

$6.65

▲ +57.96%

Market Cap $386.42M · Vol 10.99M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$386.42M

Small Cap

Div Yield

N/A

EPS Growth

+81.97%

YoY

RSI (14)

47.59

Momentum

Beta

0.68

vs Market

52W High

$40.37

83.53% below

52W Low

$2.96

124.66% above

Volume

10.99M

Avg 1.65M

P/B

5.41

Price-to-book

ROE

N/A

Return on equity

Free Float

90.56%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Capricor Therapeutics Inc (CAPR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CAPR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+62.59%

-67.84%

-77.69%

-70.38%

YTD

-76.96%

-14.52%

-6.86%

+64.60%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-105,043,950.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-39.91% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.41
P/FCF	N/A
EPS Growth	+81.97%
Outstanding Shares	58.11M

Technical Indicators

50-Day SMA	$18.24
200-Day SMA	$23.18
RSI (14)	47.59
Beta	0.68
52-Week High	$40.37
52-Week Low	$2.96

Volume Today	10.99M
Avg Daily Volume (30D)	1.65M
Relative Volume	6.68x
Volatility (10D)	225.13
Volatility (30D)	351.23
Free Float	90.56%

Analyst Consensus

HOLD

Current Price $6.65

Mean Target $9.80

52W Low$2.96 52W High$40.37

Current

Target

$2.96 $40.37

Current Analyst target

+47.37% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SKJV12

ISINUS14070B3096

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.